🚀 SRRK Stock Rockets 50%+ After FDA Nod—Q3 Losses? Wall Street Shrugs

Biotech's bad quarter? Try bullish breakout.

Scholar Rock's SRRK defies earnings miss with FDA catalyst—because in pharma, pipelines trump profits.

The FDA Effect

Shares ripped higher after regulators greenlit key talks for muscle-wasting drug apitegromab. Never mind that Q3 revenue cratered 68% YoY—this is biotech, where 'show me the data' beats 'show me the money.'

Short Squeeze Fuel

With 20% of float sold short, bears got steamrolled. One analyst's take: 'They're buying time—literally—until phase 3 data drops.'

Wall Street's Open Secret

Institutional holders know the game—lose $1.38/share today for $100/share tomorrow. Just don't ask about burn rates.

*Closer*: Another case study in how biotech valuations ignore P&Ls... until they don't. *Cue cynical VC laughter.*

Meet Your ETF AI Analyst

• Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
• Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Scholar Rock stated that it didn’t report any revenue in the third quarter of 2025, though analysts expected revenue of $56,000 during the period. It’s also worth pointing out that the company didn’t report any revenue in the same period of the year prior.

The lackluster Q3 earnings report may have some investors wondering why SRRK stock rallied today. This movement is tied to a meeting the company had with the U.S. Food and Drug Administration (FDA) earlier this week. On Wednesday, Scholar Rock had a Type A meeting with the FDA concerning its SMA program. It called the meeting “constructive” and said it has made progress on its remediation plan. The company expects its facility to be ready for reinspection by the end of the year, with a planned resubmission of its BLA for adults with SMA in 2026.

Scholar Rock Stock Movement Today

Scholar Rock stock was up 22.78% on Friday but remained down 14.58% year-to-date. Even so, the shares have rallied 13.51% over the past 12 months.

Despite today’s rally, trading of SRRK stock remained muted. Only about 42,000 shares have changed hands, compared to a three-month daily average of about 2.66 million units.

Is Scholar Rock Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Scholar Rock is Strong Buy, based on 11 Buy ratings over the past three months. With that comes an average SRRK stock price target of $46.67, representing a potential 27.37% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.